An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression.
We evaluated the efficacy of buspirone in the augmentation of antidepressant response to the serotonin reuptake inhibitors. Twenty-five patients with major depressive disorder who had failed several previous treatments for their current depressive episode were included. After failing a trial of fluoxetine or fluvoxamine, they received buspirone in addition to the serotonin reuptake inhibitor for 3 weeks in an open clinical trial. Seventeen of 25 patients had a marked or complete antidepressant response. These data provide clinical evidence suggesting that buspirone augmentation may be useful clinical alternative in depressed patients who fail to respond to a serotonin reuptake inhibitor.